Publicaciones en colaboración con investigadores/as de National Cancer Center Hospital (8)

2024

  1. Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011

    Cancer

2023

  1. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Annals of Oncology

2022

  1. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192

  2. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405

  3. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

    Nature communications, Vol. 13, Núm. 1, pp. 1878

2021

  1. Enfortumab vedotin in previously treated advanced urothelial carcinoma

    New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135

2020

  1. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120

2017

  1. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

    The Lancet, Vol. 390, Núm. 10109, pp. 2266-2277